Defeating antibiotic resistance: ISAB collaborates on new peptide treatment in EU project FORMAMP
Resistance to antibiotics remains a deadly challenge. For four years the EU project FORMAMP has explored a new nanoparticle peptide treatment that could present an alternative to antibiotics. 16 partners from academia, public health authorities, pharma and biotech companies have collaborated. Including Inhalation Sciences…
Peptides are natural born bacteria killers. And their unique way of attacking bacteria makes it difficult for the bacteria to develop resistance to them. But there’s a problem: peptides are delicate, sensitive and prone to degrade. Enter FORMAMP—and Inhalation Sciences.
“In FORMAMP we have developed nanostructure carriers for the peptides that make them more stable,” says project coordinator Lovisa Ringstad. “Focussing on local treatment of wound and lung infections. We have succeeded in stabilizing the peptide and improved its efficiency.”
New pharma treatments
The hope now is that the most successful formulations from FORMAMP will be developed into new pharma products. “The need for alternatives to conventional antibiotics is acute,” says Ringstad. “FORMAMP asked if stable formulations of antimicrobial peptides, the body’s natural defence against bacteria, could be a solution. The answer is ‘yes’ – it looks very promising.”
The tantalising prospect is that in the future children could inhale an aerosol to administer nano- formulations of antimicrobial peptides as a treatment of infectious bacterial disease. And PreciseInhale’s ability to handle nanoparticles of delicate substances has been key to FORMAMP’s success.
Dr Per Gerde, ISAB CSO: “I believe inhalation technology does have an important role to play in peptide research and therapies. So this has been a very good project for us. We are one of the few companies in the world who can deliver the quality of data needed here. We’ve been very pleased to contribute to this important cross-disciplinary project.”
Read more about FORMAMP here: